Urinary α1 microglobulin level is useful for selecting sodium‐glucose transporter 2 inhibitor or metformin for visceral fat reduction in patients with type 2 diabetes

Chiba University and Astellas Pharma Inc. signed a contract to conduct the study. The funding source did not play any role in the study design, execution, data analysis and interpretation, manuscript preparation, or decision to publish. KY received lecture fees from Astellas Pharma Inc., MSD Inc. and Sumitomo Pharma Co. Ltd. The other authors have no conflicts of interest to declare. The peer review history for this article is available at https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/dom.15188. The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request. Table S1. Baseline clinical characteristics of patients in each study drug group. Table S2. Multivariate logistic regression analysis for visceral fat area reduction responders in the ipragliflozin group. Table S3. Multivariate logistic regression analysis for visceral fat area reduction responders in the metformin group. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.